FY2026 Earnings Forecast for ALDX Issued By HC Wainwright

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – HC Wainwright dropped their FY2026 EPS estimates for shares of Aldeyra Therapeutics in a report released on Wednesday, March 18th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will earn ($0.44) per share for the year, down from their previous forecast of ($0.15). HC Wainwright currently has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at $0.09 EPS, FY2029 earnings at $0.24 EPS and FY2030 earnings at $0.21 EPS.

Separately, BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.50.

Aldeyra Therapeutics Trading Up 28.9%

Shares of Aldeyra Therapeutics stock opened at $1.83 on Friday. The firm has a market cap of $110.13 million, a PE ratio of -3.21 and a beta of 0.97. The stock has a 50 day moving average of $4.82 and a 200 day moving average of $5.03. Aldeyra Therapeutics has a 12 month low of $1.07 and a 12 month high of $6.87.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in Aldeyra Therapeutics by 275.4% in the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after acquiring an additional 1,081,257 shares in the last quarter. 683 Capital Management LLC raised its position in Aldeyra Therapeutics by 86.6% during the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after purchasing an additional 710,000 shares during the period. Kennedy Capital Management LLC raised its position in Aldeyra Therapeutics by 61.9% during the third quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company’s stock valued at $5,806,000 after purchasing an additional 425,245 shares during the period. Bank of America Corp DE lifted its stake in shares of Aldeyra Therapeutics by 590.5% in the 3rd quarter. Bank of America Corp DE now owns 390,078 shares of the biotechnology company’s stock valued at $2,036,000 after purchasing an additional 333,587 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in shares of Aldeyra Therapeutics by 49.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 947,551 shares of the biotechnology company’s stock valued at $4,946,000 after purchasing an additional 313,395 shares during the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics News Summary

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Insider buy — Director/officer Michael Alfieri purchased 5,000 shares at about $1.42, increasing his stake; a small sign of insider conviction amid the selloff. SEC filing: insider purchase
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating and set a $2.00 price target (down from prior levels), signaling limited upside in analysts’ views even as they adjust forecasts. HC Wainwright reaffirms neutral
• Negative Sentiment: FDA rejection — The third CRL for reproxalap (NDA for dry eye) is the primary driver of the crash; the FDA cited insufficient efficacy, prompting the market to reprice the program’s value and near‑term revenue prospects. Zacks: FDA issues third CRL
• Negative Sentiment: Analyst cuts — HC Wainwright materially trimmed EPS forecasts across FY2026–FY2030 (Q4 2026 and multi‑year outlooks lowered), and slashed prior price expectations, reflecting weaker commercialization prospects and pushing sentiment lower. Benzinga: HC Wainwright coverage
• Negative Sentiment: Litigation risk — Multiple law firms (Pomerantz, Levi & Korsinsky, Block & Leviton, others) have launched securities‑fraud investigations and class‑action solicitations citing alleged misstatements about reproxalap’s prospects, increasing legal overhang and downside risk for shareholders. PR Newswire: Pomerantz investigation
• Negative Sentiment: Bearing bets — Elevated put‑option activity and reported heavy bearish trading suggest traders are positioning for additional downside or volatility, which can amplify moves. American Banking News: put option activity

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.